Publications by authors named "Paul G Steinkuller"
Article Synopsis
- Lower doses of bevacizumab are now being used for treating type 1 retinopathy of prematurity, but there's a lack of long-term data on their effectiveness.
- The study aimed to assess ocular outcomes at 12 months for infants who received various doses of bevacizumab, ranging from 0.625 mg to 0.031 mg.
- Results indicated that 75% of infants had follow-up at 12 months, with a small percentage showing significant refractive errors and minimal ocular abnormalities, suggesting a need for ongoing monitoring of long-term outcomes.
Purpose: To measure serum levels of bevacizumab and to compare serum levels of free vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) in infants who were treated with either intravitreal injection of bevacizumab (IVB) or laser for type 1 retinopathy of prematurity (ROP).
Methods: Twenty-four infants with type 1 ROP were randomized into three treatment groups: IVB at 0.625 mg per eye per dose, IVB at 0.
Purpose: To explore the association of autonomic agents with the development and severity of retinopathy of prematurity (ROP).
Methods: The medical records of all preterm infants screened for ROP were retrospective reviewed. The association between development and severity of ROP and the use and dose(s) of autonomic agents was analyzed, after adjustment for the covariates gestational age, weight, development of septicemia, intraventricular hemorrhage, and respiratory distress syndrome.
Purpose: To summarize the available data on pediatric blinding disease worldwide and to present current information on childhood blindness in the United States.
Methods: A systematic search of world literature published since 1999 was conducted. Data also were solicited from each state school for the blind in the United States.